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SUMMARY
Typical absence seizures (ASs) are nonconvulsive epileptic events which are commonly
observed in pediatric and juvenile epilepsies and may be present in adults suffering from
other idiopathic generalized epilepsies. Our understanding of the pathophysiological mech-
anisms of ASs has been greatly advanced by the availability of genetic and pharmacological
models, in particular the c-hydroxybutyrate (GHB) model which, in recent years, has been
extensively used in studies in transgenic mice. GHB is an endogenous brain molecule that
upon administration to various species, including humans, induces not only ASs but also a
state of sedation/hypnosis. Analysis of the available data clearly indicates that only in the
rat does there exist a set of GHB-elicited behavioral and EEG events that can be confidently
classified as ASs. Other GHB activities, particularly in mice, appear to be mostly of a seda-
tive/hypnotic nature: thus, their relevance to ASs requires further investigation. At the
molecular level, GHB acts as a weak GABA-B agonist, while the existence of a GHB receptor
remains elusive. The pre- and postsynaptic actions underlying GHB-elicited ASs have been
thoroughly elucidated in thalamus, but little is known about the cellular/network effects of
GHB in neocortex, the other brain region involved in the generation of ASs.
Introduction
Typical absence seizures (ASs) are brief (3–30 second) nonconvul-
sive epileptic events that consist of impairment of consciousness
accompanied in the electroencephalogram (EEG) by 2.5–4 Hz
“spike and slow-wave discharges” (SWDs) (Figure 1A) [1]. ASs
start and end abruptly and there is no aura or postictal depression
[1,2]. The extent of the impairment of consciousness is variable
among individuals, and between seizures in the same individual,
and is generally defined by a lack of responsiveness to external
stimuli during the seizure, a temporary interruption of an ongoing
task (although simple repetitive tasks can continue during ASs)
and/or the inability to recall, after seizure termination, a stimulus
that had occurred ictally [2,3]. Although ASs are part of a more
complex phenotype in many idiopathic generalized epilepsies,
they are the only clinical symptom in childhood absence epilepsy
(CAE), a common pediatric epilepsy, which accounts for about
10% of all childhood epilepsies [4–6]. CAE generally affects chil-
dren between 4 and 10 years, has a remission rate of between
20% and 70% [1,7], and a clear polygenic inheritance [1,8,9].
The current pharmacological treatment of ASs is based on “clas-
sical” antiabsence drugs, namely ethosuximide and valproate,
each effective in about 50% of patients [10]. Both drugs have
recently been shown to be more efficacious than newly developed
drugs, such as lamotrigine [10]. In addition, antiepileptic drugs
that are effective against convulsive seizures (such as carbamaze-
pine and phenytoin) are generally reported to be either ineffective
or to aggravate human ASs [11–14], making the pharmacological
profile of ASs unique.
The pathophysiological mechanisms of typical ASs are only
partly understood, but it is well established that ASs are generated
by abnormal electrical activity in reciprocally connected thalamic
and cortical territories, that is, the thalamocortical (TC) network
[1,15]. Indeed, the integrity of all of the main components of the
TC network, that is, thalamic nuclei, the nucleus reticularis thal-
ami (NRT), and the cortex, is essential for the full expression of
the behavioral and EEG features of experimental ASs [1,16].
Imaging studies in humans have shown that the cerebellum and
limbic structures (such as the hippocampus) are not involved in
the expression of typical ASs [17–19], although they may play a
role in atypical ASs [20].
Various genetic and pharmacological animal models of ASs have
been developed to help understand the mechanisms underlying
the generation of these nonconvulsive seizures. Two polygenic rat
strains, namely GAERS (genetic absence epilepsy rats from Stras-
bourg [21]) and WAG/Rij (Wistar Albino Glaxo rats from Rijswijk
[22]) are the best-characterized genetic models of ASs consisting
of 7–9 Hz SWDs and concomitant behavioral arrest in the absence
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Figure 1 EEG recordings of human ASs and EEG activities elicited by GHB in various animal species. (A) Scalp EEG recordings from three childhood
absence epilepsy (CAE) patients showing the characteristic 3–4 Hz SWDs, the EEG hallmark of ASs. Note the sudden onset and termination of the SWDs
from a desynchronized EEG background, and the different SWD morphology among patients (i.e., different amplitude of the spike component both within
a SWD (2,3) and in different patients (1–3). (B) Administration of GBL (30 mg/kg i.v.) to healthy human volunteers produces 2–3 Hz delta waves (2) that
appear suddenly from a desynchronized EEG background (1). After 10–15 min, the delta waves become continuous (3). This EEG output can be obtained
for a range of GBL and GHB doses (3–6 g GHB i.v.). Doses exceeding 7–8 g i.v. produce, following the EEG manifestations shown in (2) and (3), a burst-
suppression pattern (4) where bursts of slow EEG waves interrupt cortical silence. This EEG activity is invariably accompanied by a state of deep hypnosis/
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of other neurological abnormalities. In addition, several mono-
genic mouse models of ASs have been described (e.g., stargazer,
lethargic, tottering, etc. [1,23,24], although these models also
present additional neurological phenotypes such as ataxia.
Pharmacological models of ASs have also been developed.
Historically, c-hydroxybutyric acid (GHB), pentylenetetrazol
(PTZ) (at low doses, 20–30 mg/kg), and penicillin (at high doses,
intramuscularly) have been the drugs most commonly used to
induce ASs in various animal species [25]. Although, undoubt-
edly, genetic models of ASs have many advantages, both in theo-
retical (i.e., construct validity) and in practical terms, the use of
pharmacological models, and in particular the GHB model, has
increased in recent years. One of the reasons is that AS-inducing
drugs can be applied systemically to transgenic mice to investigate
the contribution of individual genes to the expression of ASs.
Crossing a genetic mouse model of ASs with a transgenic mouse
would also be a viable alternative, but it is more time consuming
because, to control for differences in genetic backgrounds, the
resulting strain needs to be backcrossed with the recipient strain
for several generations [24,26]. Moreover, using a substance capa-
ble of inducing ASs in various species, it is possible to combine a
broad range of invasive and noninvasive techniques, pharmaco-
logical interventions, and behavioral paradigms to allow a more
comprehensive definition of both the face and the predictive
validity of an AS model.
This review provides a critical evaluation of the GHB model of
ASs and its relevance to the human condition. We start by describ-
ing the EEG and behavioral correlates of exogenous GHB adminis-
tration in humans and compare them to those in nonhuman
primates, cats, and rodents. We then review the brain regions
involved in the expression of GHB-elicited ASs and the molecular
targets of the GHB in the brain. What emerges from this analysis is
that only in the rat does there exist a subset of GHB-elicited
behavioral and EEG events that can be confidently classified as
ASs. In other species, further studies are required to assess the
potential relevance of other GHB-induced activities (i.e., sedation/
hypnosis) to ASs. At the molecular level, the thalamic GABA-B
receptor-mediated pre- and postsynaptic actions that underlie
GHB-elicited ASs have been elucidated, while its cellular and net-
work effects in the neocortex are still largely unknown.
Brief History of GHB
GHB was originally synthetized, starting from c-butyrolactone
(GBL), by Henri Laborit in 1960 in an attempt to create a novel
anesthetic agent that would cross the blood-brain barrier and act
as a GABA analog [27]. In humans, however, GHB was never
used as an anesthetic agent in isolation; although it initially gained
some popularity as a sedative/hypnotic agent, or as an adjuvant to
other anesthetics [28,29]. It was subsequently discovered that
GHB is actually an endogenous brain substance, raising the possi-
bility of a role for endogenous GHB in natural sleep [30]. In subse-
quent years, the pathways which control the brain levels of GHB
and its conversion to GABA were also described [31].
Notwithstanding initial claims that GHB had some antiepileptic
properties [27]; anecdotal evidence suggested that GHB could
induce ASs in subjects with a history of generalized seizures [32].
Nonetheless, it was animal studies that first indicated that the
exogenous application of GHB induces a state that bore more
resemblance to ASs than to anesthesia/sleep. Historically, the first
evidence of the ability of GHB to elicit nonconvulsive, generalized
seizures in a na€ıve animal came from a study in the cat [33]. This
finding was partially supported by studies in monkeys [34] and
rats [35], but it was mostly the work of Carter Snead’s group that
established GHB as a solid model of ASs [25,36,37].
Importantly, it was later established that GBL, which is per se
biologically inactive [34,38,39], can be converted into GHB by a
lactonase in the plasma and liver, and therefore acts as a GHB pro-
drug [40]. GBL has now supplanted GHB for the induction of
experimental ASs because of its faster onset of action [41], but,
given that GHB is the active form of the drug, for clarity, we will
thereafter continue referring to the “GHB model” or “GHB-elic-
ited” activity, even if the administered drug was actually GBL.
For the sake of completeness, it should be noted that chronic
GHB administration has found some therapeutic applications in
humans, for instance in the treatment of narcolepsy and alcohol-
withdrawal syndrome. Moreover, the abuse potential of GHB is
becoming increasingly recognized. These aspects of therapeutic
use and abuse of GHB will not be described here, and the reader is
referred to relevant reviews on the subject [42–44].
EEG and Behavior Following Acute GHB
Administration: Hypnotic and Seizure-
Like Activities
Species-Specific Effects of GHB Administration
GHB has been characterized as a model of ASs across various
species for more than 50 years. Given that the terminology
anesthesia. (see Figure 2 for a comparison of the effect of GHB in a patient with generalized epilepsy.) (C) In monkeys, the desynchronized EEG (1) evolves
into an EEG pattern of 3 Hz slow/delta waves following administration of 200 mg/kg/s.c. of GBL (2). High doses of GHB (500 mg/kg/i.v.) produce, in addition
to the EEG manifestations shown in (2), a clear burst-suppression pattern (3). (D) In cats, an i.p. injection of GHB 200 mg/kg induces first an intermittent (2)
and then a continuous hypersynchronous EEG (3). The EEG is punctuated with spikes that are found either alone or within 2–3 Hz SWCs. GHB 400 mg/kg
i.p. induces, in addition to the EEG manifestations shown in (2) and (3), a burst-suppression pattern (4). (E) In rats, a dose of 200 mg/kg GHB i.p. elicits at
first isolated 5–6 Hz SWDs (2) that emerge from a desynchronized EEG background (1). Within 10–15 min, this EEG activity becomes continuous and its
frequency slows down to 4–5 Hz (3). Note that SWCs are not always discernible, and slow waves without spikes are sometimes prevalent. A dose of
400 mg/kg GBL induces, subsequently to the EEG manifestations shown in (2) and (3), a burst-suppression pattern (4). (F) In mice, a dose of 70 mg/kg GBL
i.p. induces first the appearance of 4–5 Hz SWDs (2, top trace) or 4–5 Hz waves (2, bottom trace) that appear intermittently in the EEG. This EEG activity
gradually becomes continuous and its frequency slows down (3), still exhibiting spike and waves (top trace) or waves only (bottom trace). A dose of
150 mg/kg GBL elicits, following the EEG manifestations shown in (2) and (3), a burst-suppression pattern (4). Reproduced (with and without modification)
from [2] A1; [160] A2; [14] A3; [32] B1-2-4; [47] B3; [54] C1-2; [51] C3; [33] D; [58] E1-2-3; [64] E4; [155] F1, F2-3 (top); [69] F2-3 (bottom); [70] F4.
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used to describe the EEG and behavioral effects of GHB varies
markedly across studies, we will describe the effects of GHB
administration in various animal species, while being faithful
to the original terminology used in each of the original reports
(Table 1). In view of the peculiar pharmacological profile of
human ASs [25], special attention will be given to the sensitiv-
ity of the various GHB-elicited activities to antiepileptic drugs
(Table 2).
Humans
Early reports described the effect of GHB, administered intra-
venously (i.v.) in doses of 3–10 g (~40–140 mg/kg), on the
EEG and behavior of healthy volunteers [27,32]. These early
experiments are of particular interest because they show
effects of GHB at higher doses than those currently used ther-
apeutically.
Table 1 EEG activities evoked by GHB in different species
Species Drug and dose Route
Stage2a Stage2b
ReferencesFrequency Description Frequency Description
Human
Human GHB 3–6 g i.v. ? ? 2–3 Hz Monomorphic delta
waves
[32]
Human GBL 25–30 mg/Kg i.v. 2–5 Hz Slow waves 2–2.5 Hz Slow waves [47]
Non-human primate
Rhesus monkey GHB 200–400 mg/kg i.v. ? ? 2.5–3 Hz High-voltage slow waves
often associated with
spikes (note spikes
are not visible in the
figures)
[51]
Marmoset
monkey
GBL 200 mg/Kg s.c. ? ? 3 Hz SWDs with spikes that
are not discernible
[54]
Cat
Cat 200–400 mg/Kg i.p. 2–3 Hz Intermittent
hypersynchronous
bursts
2.5 Hz Continuous
hypersynchronous waves
composed of one of three
complexes, that is,
slow waves, a slow wave
followed by a spike or
a slow wave followed by
a short polyphasic burst
discharge.
[33]
Rat
Sprague-Dawley 500 mg/Kg GHL/
700 mg/Kg GHB
i.p. ? Intermittent
hypersynchronous waves
2–3 Hz Continuous
hypersynchrony
[35]
Sprague-Dawley 400 mg/Kg GBL i.p. ? Brief bursts of spikes ? Continuous spiking and/
or spike and slow wave
[64]
Sprague-Dawley 100 mg/Kg GBL i.p. 4–6 Hz SWDs ? Continuous SWDs [124]
Sprague-Dawley 100 mg/Kg GBL i.p. 5–6 Hz Bursts of spikes ? Continuous spiking [148]
Sprague-Dawley 150 mg/Kg GBL i.p. 7–9 Hz SWDs ? ? [25]
Sprague-Dawley 100 mgkg GHB i.p. 6–9 Hz SWDs ? ? [62]
Sprague-Dawley 200 mg/Kg GBL i.p. 6–7 Hz SWDs ? ? [87]
Wistar 200 mg/Kg GHB i.p. 5–6 Hz Bursts of
hypersynchronous waves
4–5 Hz Continuous
hypersynchrony
[58,59]
Wistar 100 mg/Kg GBL i.p. 4–5 Hz SWDs ? [158]
Wistar 200 mg/Kg GBL i.p. 4–5 Hz SWDs ? Continuous SWDs [158]
Mouse
Ddy 100 mg/Kg GHB or GBL i.p. 3–6 Hz SWDs 3–6 Hz SWDs [70]
C57BL/6J 70 mg/Kg GBL i.p. 3–5 Hz SWDs 3–5 Hz SWDs [69]
BALB/cJ 100–150 mg/Kg GBL i.p. ? Burst of hypersynchronous
slow waves
? Hypersynchronous slow
waves and/or spiky EEG
[68]
C57BL/6 100–150 mg/Kg GBL i.p. ? Hypersynchronous slow
waves and/or SWD
? Hypersynchronous slow
waves and/or SWD
[157]
The description of stage 2a and 2b reports the wording used in the original papers. For further details of the classification of stage 2a and 2b see
main text. i.p. intraperitoneal; i.v. intravenous; s.c. subcutaneous; NA/?: data not available.
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Sedation appeared within 5–10 min from the beginning of the
administration of the drug [32,45,46]. This was accompanied by
the disappearance of the alpha rhythm in the EEG along with an
increase in theta activity, without any apparent change in behav-
ior [32]. This stage was followed by the occurrence of high-ampli-
tude delta waves in the EEG (Figure 1B3), while the subject
appeared to be drowsy. At a dose of 3 g i.v., the subjects des-
cended into a state of reversible sleep, but still responded to sen-
sory stimulation which produced a temporary disappearance of
the delta waves and EEG desynchronization for the duration of
the stimulus. Furthermore, the subjects had difficulty in perform-
ing mental calculations, pointing to a disruption of cognitive func-
tion [32]. Another study using GBL (20–30 mg/kg i.v.) also
produced 2–5 Hz slow waves, which appeared initially as inter-
mittent bursts (Figure 1B2) and then became continuous within
15 min of the injection [47]. Interestingly, the author of this study
claims that consciousness was spared in these subjects, that is,
although the subjects felt mildly intoxicated, they were aware of
their surroundings and could perform tasks such as counting light
flashes. During this behavioral output, the slow waves were
replaced by a desynchronized EEG [47]. At doses of 4–5 g, the
sensory threshold to awaken a subject who was in the delta wave
stage was higher, and only painful stimulations could produce a
desynchronized EEG and a behavioral response (e.g., movement).
With doses of 7–8 g of GHB, the appearance of delta waves was
followed by another characteristic stage: the EEG displayed
cortical silence, interrupted by K-complexes (Figure 1B4), while
behaviorally, the subject was unresponsive to external stimuli,
including nociceptive ones, that is, the subject was anesthetized
[32]. This EEG manifestation, called “burst-suppression pattern”,
is also characteristic of the anesthetic state induced by thiopental,
propofol, and isoflurane [48–50]. In summary, in healthy volun-
teers, there is no evidence that GHB induces SWDs or ASs, and,
importantly, no antiabsence drug has been tested against the
GHB-elicited slow/delta waves, burst-suppression pattern, and
respective behaviors that are elicited by GHB.
However, GHB has been shown to have a pro-epileptic effect in
patients with a history of (nonidentified) generalized seizures
[32]. Indeed, in these patients, SWDs were observed in the EEG
within 2 min of an i.v. bolus injection of 3 g of GHB (Figure 2B).
These SWDs, however, were short lived: within few minutes, the
spikes started to slowly disappear and the frequency of the EEG
large amplitude waves became progressively slower (Figure 2C),
eventually giving rise to full-blown delta waves (Figure 2D) simi-
lar to those observed after administration of an equivalent dose of
GHB to healthy subjects (see Figure 1B3). Unfortunately, no
(A) (B) (C) (D)
Figure 2 GHB administration induces SWDs in subjects with generalized epilepsy. (A) EEG from a patient with generalized epilepsy prior to GHB
administration. Bolus i.v. injection of GHB (3 g) induced SWDs in the EEG within 2 min from the injection (B). SWDs were of short duration and gave rise to
slow/delta waves (C), initially punctuated with spikes (compare with Figure 1B). The EEG spikes gradually disappeared from the slow/delta waves
background (D) so that the EEG became similar to the one reported for GHB administration in healthy subjects (compare with Figure 1B). Modified from
[32].
Table 2 Comparison of the pharmacological profile of human ASs and GHB-elicited stage 2 activities (ASs and hypnosis). For further details of the
classification of stage 2 activities into hypnosis and ASs see section 3.2
Antiabsence drugs Drugs ineffective or worsening ASs
ReferencesEthosuximide Valproate Lamotrigine Carbamazepine Phenytoin
Human ASs (CAE) ↓ ↓ ↓ ↓/= ↑/= [10–14]
GHB-elicited stage 2 activities
Human ? ? ? ? ? NA
Monkey ↓ ? ? ? ↑/= [52–54]
Cat ? ? ? ? ? NA
Rat ↓ ↓ ? ↑ ↑ [25,59,62,63]
Mouse ↓ = ? ? ? [70]
↓: decrease of ASs; ↑: exacerbation of ASs; =: no effect on ASs; NA/?: data not available.
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description of the behavioral correlates (e.g., impairment of con-
sciousness) that accompanied the EEG expression of SWDs was
provided and no antiabsence drug was tested against the GHB-
elicited SWDs [32].
Nonhuman Primates
I.v. administration of GHB in nonhuman primates elicited similar
patterns of EEG activity to those seen in healthy humans (Fig-
ure 1C). In rhesus monkeys, a low dose of GHB (100–200 mg/
kg) induced low-voltage slowing of the EEG, accompanied by
drowsiness [51]. At a dose of 400 mg/kg [52], a continuous
activity, characterized by 2–3 Hz high-voltage slow waves,
appeared in the EEG. Animals were unresponsive to sensory
stimulation and displayed occasional stereotyped movements and
myoclonic jerks. At even higher doses (>500 mg/kg), animals
started to display generalized myoclonic jerks accompanied by a
burst-suppression EEG pattern (Figure 1C3) [51]. These EEG and
behavioral effects were blocked by ethosuximide, given both
acutely (100 mg/kg i.v.) and chronically (serum concentration:
140 lg/mL), and were worsened by chronic treatment with phe-
nytoin (serum concentration: 14 lg/mL) (Table 2) [52,53]. These
results have recently been replicated in marmoset monkeys with
i.v. injection of 200 mg/kg GBL producing a similar slow-wave
EEG pattern (Figure 1C2) and associated behavior, both of which
were reversed by chronic treatment with ethosuximide (30 mg/
kg/day) [54].
On the basis of the co-occurrence, and unique pharmacological
profiles, of the behavioral output and EEG paroxysm, it was
argued that the GHB-elicited activity in monkeys modeled the
spontaneous ASs of idiopathic generalized epilepsy. However, as
in healthy humans treated with GHB, the presence of spikes
superimposed to the slow/delta waves is not discernible in the
EEG recordings of GHB-treated monkeys, and in contrast to spon-
taneous ASs in humans, the slow/delta wave activity could be
evoked by auditory stimulation [51].
Cats
Injection of GHB, either i.v. or intraperitoneally (i.p.), produced
EEG and behavioral changes similar to those that have been
described in primates [33,55,56], with some important differ-
ences: no drowsiness was observed at low doses (e.g., 60 mg/kg),
and the EEG slowing was accompanied by the presence of spikes
in the EEG [33]. Upon i.p. administration of 200–400 mg/kg of
GHB, the animal first produced an EEG pattern defined as “2–
3 Hz intermittent hypersynchronous bursts” (Figure 1D2) [33],
while it was in a crouching position with its eyes open. This gradu-
ally progressed into a pattern of “2.5 Hz continuous hypersyn-
chrony, where each complex is composed of either a slow wave, a
slow wave followed by a spike or a slow wave followed by a poly-
phasic burst discharge” (Figure 1D3) [33]. During this EEG state,
the animal had fixed gaze and made repetitive head movements.
Sensory stimulation disrupted the EEG synchrony and awakened
the cat. Following a dose of 400–600 mg/kg, the EEG progressed
through the previously described continuous and intermittent
EEG stages and then showed a burst-suppression pattern (Fig-
ure 1D4) that was accompanied by myoclonic jerks [33]. No an-
tiabsence drugs were tested against the EEG and behavioral
phenotype elicited by GHB in cats.
Rats
The effects of GHB in rats are by far the best described among all
species. Systemic administration of GHB (25–100 mg/kg) in Wi-
star rats produced an increase in slow-wave sleep [57,58] that per-
sisted for up to 4 h. Higher doses (200 mg/kg) in Wistar rats were
reported instead to induce two types of activity, distinguishable
both at the EEG and behavioral level [58,59]. At first intermittent
bursts, that is, short (5–8 second) periods of hypersynchronous 5–
6 Hz “spikes and waves”, appeared on the EEG (Figure 1E2). Con-
comitantly with the start and end of these intermittent bursts of
“spike and waves” the animals froze with their eyes open. These
intermittent bursts gradually increased in length and within
10 min evolved into a continuous hypersynchronous state at a
lower frequency (4–5 Hz) (Figure 1E3). This state lasted for about
20 min during which the animal stopped moving altogether and
appeared to be in a sedated state. As shown in Figure 1E3, the
EEG activity in this continuous hypersynchronous state appeared
to be less regular than during the intermittent bursts, with slow
waves and spikes not always associated into spike-wave com-
plexes (SWCs). After 20 min, the intermittent bursts, and their
associated behavioral output, gradually reappeared on the back-
ground of a desynchronized EEG. The authors of this study posited
that the intermittent bursts of “spike and waves”, with their clear
transitory interruption of directed movement, paralleled sponta-
neous ASs [58]. No attempt was made to correlate the continuous
synchronized state with human pathology. A similar progression
between an intermittent synchronized EEG state and a continu-
ous synchronized EEG state had been described in an early study
[35] where equimolar doses of 5.8 mM GHB or GBL (equivalent
to ~700 mg/kg GHB and ~500 mg/kg GBL) were administered to
Sprague–Dawley rats. In addition, these higher doses of GHB and
GBL produced a reversible burst-suppression pattern (for 50–
80 min) that was concomitant with a loss of the righting reflex
(Figure 1E4). In subsequent studies of GHB-induced activity,
other fine behavioral phenotypes were also observed. During the
intermittent bursts with behavioral arrest, rats were seen to dis-
play facial myoclonus and vibrissal twitching [25], features that
are also present in genetic rat models of ASs [60,61]. These mani-
festations are said to represent the correlates of some behavioral
automatisms (e.g., lip smacking, eyelid flutters, chewing) that are
observed during spontaneous ASs in humans [2].
Importantly, the intermittent and continuous hypersynchro-
nous EEG states in the rat (Figure 1E2 and E3) had a pharmaco-
logical profile strikingly similar to the one of human ASs, being
blocked by drugs that are effective against spontaneous human
ASs (e.g., ethosuximide and valproate) and exacerbated by drugs
that are effective on convulsive seizures (e.g., carbamazepine and
phenytoin) [25,59,62,63]. In addition, ethosuximide was ineffec-
tive in blocking the burst-suppression pattern (Figure 1E4), sug-
gesting that this state is distinct from GHB-elicited ASs [64].
It is noteworthy that even though the initial study posited that
only GHB-elicited SWDs, accompanied by behavioral arrest with
sudden onset and termination (Figure 1E2), could model sponta-
neous human ASs [58], in the subsequent literature, all of the
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activities evoked by GHB in the rat (with the exclusion of the
burst-suppression pattern) were said to reproduce ASs [25,36,64].
Nonetheless the EEG and behavioral effects of GHB-elicited ASs
seem to vary among experiments and even within the same
experiment (see for example Figure 3 in [65] where upon injec-
tion of 100 mg/kg GBL there is a clear slowing down of the fre-
quency of the GHB-elicited EEG activity with time). This is also
apparent in the frequencies of GHB-elicited SWDs and continuous
hypersynchrony, which have been reported to vary across the
range 3–9 Hz, and in the different terminology that researchers
have used to describe these EEG manifestations (Table 1). It is
currently unclear how much these differences are related to rat
strain (with experiments being conducted mainly on Wistar and
Sprague–Dawley rats) (Table 1) or doses of GHB/GBL.
Mice
Administration of low doses of GBL (50 mg/kg) in mice has
generally been reported to have no effect on the EEG [66] and, in
contrast to rats, failed to induce slow-wave sleep [67,68]. Instead,
a slightly larger dose (70 mg–100 mg/kg GBL) induced, after 5–
10 min from the injection, a state that was generally described as
EEG hypersynchrony [67,68] or SWDs [69–71]. The effect of GBL
administration was generally reported to last less than in the rat,
totaling 30 min to 1 h in different studies [69,70,72]. The
frequencies reported for the GHB-elicited EEG activities are gen-
erally lower than in the rat and they vary around 3–6 Hz
(Table 1). In addition, although it is never discussed directly in
the literature, it appears that the so-called SWDs in the mouse are
often less regular than in the rat, and clearly discernible SWCs
(where spikes and waves are phase-locked) are seldom observed
(Figure 1F2). Indeed, the most prevalent EEG activity appears to
be a general shift of EEG activity to lower frequencies with occa-
sional spikes (Figure 1F3). Higher doses of GBL (200–400 mg/kg)
induced an EEG burst-suppression pattern and, behaviorally, a
loss of the righting reflex (Figure 1F4) [66], as observed in other
species.
The pharmacological profile of GHB-induced SWDs in mice has
not been characterized as thoroughly as in the rat. Notably, GHB-
induced continuous hypersynchronous events and SWDs were
reduced by ethosuximide (200 mg/kg), while valproate (100 mg/
kg) was ineffective [70]. Moreover, no data are available on the
effects of carbamazepine or phenytoin on GHB-elicited responses
in mice.
Ontogeny of GHB-Elicited ASs
Pediatric ASs, characteristic symptom of CAE, have a peculiar
developmental profile characterized by a high-remission rate in
adolescence [1]. Importantly, this developmental profile is dif-
ferent from that of all genetic models of ASs studied, where
instead ASs frequency and duration are reported to increase
throughout the lifespan of the animal [16,73]. In the case of
the GHB model, the ontogeny of GHB-elicited ASs was care-
Figure 3 Systemic GHB administration induces three stages of activity that are distinguishable at the EEG and behavioral level. GHB (or its prodrug GBL)
dose-dependently induces marked changes in the EEG and behavior in various animal species (humans, monkeys, cats, rats, and mice). These GHB-elicited
activities can be grouped in 3 stages (top) that are reached in succession with increasing concentrations of GHB. The wearing off of the drug also follows
the 3 stages but in an inverse order. The threshold dose to reach each stage is illustrated together with the route of administration. Low doses of GHB
(stage 1) induce drowsiness and non-REM sleep. Medium doses of GHB induce a peculiar phenotype that is generally thought to mimic human absence
seizures and/or light hypnosis, and can be divided in two substages (a and b). During stage 2a, intermittent EEG paroxysms emerge from a background of
desynchronized EEG. During stage 2b (that is reached with the same threshold dose of stage 2a), there is a light hypnotic state, characterized by changes
in body posture and decrease in muscle tone, while the EEG paroxysms become continuous. At high doses of GHB, a behavioral state of deep hypnosis/
anesthesia is reached (stage 3) which is accompanied by a burst-suppression pattern in the EEG. p.o.: per os; i.v.: intravenous; i.p.: intraperitoneal; NA/?:
data not available.
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fully studied in the rat using 200–400 mg/kg of GBL [64]. In
young animals (less than postnatal day 14, P14), GHB only
produced EEG slowing and a burst-suppression pattern. Some
intermediated spiking activity was evoked around P16, but full-
blown SWDs were only observed after P28 [64]. No differences
were reported for GHB-evoked EEG activities among adult ani-
mals of different age (P30-P90). Thus, in the GHB model,
SWDs can only be evoked in the adult brain, strengthening the
similarity to other genetic models of ASs and the difference
with humans.
Classification of GHB-Elicited Effects: Which
Stage Models Human ASs?
From the description provided in the previous sections, it is clear
that the effects of GHB on the EEG and behavior of different spe-
cies vary dose-dependently on a spectrum from drowsiness/sleep-
facilitating effects, to activities that resemble spontaneous human
ASs, to hypnosis and anesthesia. Expanding on the classification
originally introduced by Schneider for humans [32] and by Snead
for rats [64,74], here we propose a structured classification of
GHB-elicited activities into three stages, each with characteristic
EEG and behavioral correlates across all animal species (Figure 3).
These three stages are reached in succession and with different
thresholds of GHB concentration, and the wearing off of the drug
follows the same stages but in the reverse order (Figure 3).
Stage 1: Drowsiness/Sleep-Facilitation
GHB produces drowsiness and a slowing down of the EEG and/or
facilitates an increase in slow-wave sleep. This stage is generally
not observed in cats and mice, but is present in primates and rats
(Figure 3).
Stage 2: Absence Seizures/Light Hypnosis
High-amplitude slow waves and/or spikes appear in the EEG.
Primates have very prominent 2–3 Hz slow/delta waves but no
clear spikes in the EEG. Rats display a range of activities from
SWCs (at 4–9 Hz) to slow/delta waves. Cats, in addition to 2–3 Hz
SWDs and slow waves, also present intermittent trains of spikes.
Generally, slow waves/SWDs start to occur intermittently in well-
isolated short periods (~5 seconds in humans and cats; ~5–8 sec-
onds in rats) from a background of desynchronized EEG, and are
invariably concomitant with a behavioral arrest and, in some spe-
cies, behavioral automatisms (stage 2a) (Figure 3). Then, in all
species, the EEG slow waves/SWDs become continuous, their fre-
quency tends to slow down (humans 2–5 Hz to 2–2.5 Hz; cats 2–
3 Hz to 2.5 Hz; rats 5–6 Hz to 4–5 Hz) and immobility sets in
(stage 2b) (Figure 3). This continuous EEG activity is reversible
and can be temporarily interrupted by sensory stimulation, which
produces both a behavioral output and a desynchronized EEG.
The behavior (e.g., body posture and muscle tone) observed in
stage 2b is suggestive of a light hypnotic state (Figure 3).
Stage 3: Deep Hypnosis/Anesthesia
The slowing down of the EEG frequency progresses and, in all spe-
cies, evolves into an EEG burst-suppression pattern similar to
what is observed in propofol or isoflurane anesthesia, that is, elec-
trical silence interrupted by bursts of spikes (Figure 3) [48,49].
Behaviorally, this state is similar to deep hypnosis/anesthesia. In
rodents, there is a characteristic loss of the righting reflex. Myo-
clonic jerks are sometimes observed in monkeys and cats.
Does GHB Induce ASs in All Animal Species?
In all animal species examined, concentrations of GHB that reach
stage 2 and stage 3 induce a behavioral phenotype that is indica-
tive of impairment of consciousness. However, many hypnotic
drugs besides GHB, such as barbiturates [33], also produce an
impairment of consciousness. To model an AS, the impairment of
consciousness should be sudden, transient, and devoid of convul-
sion. Moreover, an impairment of consciousness can be inferred
by an external observer only if it has a behavioral correlate, such
as a transient behavioral arrest; so, only the intermittent EEG par-
oxysms found in stage 2a fully meet these requirements (Table 3).
In addition, the EEG paroxysm of human ASs has a unique SWD
morphology. However, this human EEG morphology can vary
quite substantially compared to the “textbook” representation, as
often the spike component of the SWC is reduced in amplitude or
appears to be buried inside the wave, in particular during the ter-
minal phase of a SWD (Figure 1A2 and A3) [75]. Nonetheless, an
EEG spike component can always be observed, in at least some
SWCs.
In the case of primates, several observations challenge the clas-
sification of stage 2 GHB-induced activities as being similar to
spontaneous human ASs. In both healthy humans and monkeys,
the EEG of stage 2 GHB-induced activities is characterized by
high-amplitude 2–3 Hz slow waves with no spike component. It is
Table 3 Comparison of stage 2 GHB-elicited activities and human ASs
EEG Behavior Pharmacological profile
Stage2a Stage2b Stage2a Stage2b Stage2a Stage 2b
Human +  ?  ? ?
Monkey ?  ?  ? ++
Cat +++ + +  ? ?
Rat ++ + +  +++ +++
Mouse +  ?  + +
+: some degree of similarity to human ASs; ++: similar to human ASs; +++: closely matching human ASs; : different from human ASs. See main text
for further details.
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unlikely that this is due to technical limitations in the original
EEG recordings [51], as the same results have been recently repli-
cated in marmoset monkeys [54]. Moreover, in an earlier human
study [32], GHB was able to trigger proper SWDs but only in
patients with a history of generalized seizures. This effect was tem-
porally restricted to the transition between stage 1 and stage 2 of
the GHB action (Figure 2). Upon cessation of the SWDs, the usual
stage 2 GHB-induced delta waves (devoid of EEG spikes) appeared
in the EEG [32]. Finally, in humans [47] and in monkeys [51],
the delta waves could also be triggered by auditory or visual stim-
ulations, a feature that is not present in typical human ASs. The
practice of defining the slow/delta waves as ASs seems to be dri-
ven more from the pharmacological profile of this evoked activity
than from similarities to the human condition. It is striking that
stage 2 GHB-evoked activities are abolished by ethosuximide and
exacerbated by phenytoin. Nonetheless, given that (1) EEG parox-
ysms are devoid of a spike component, (2) the behavioral corre-
lates are similar to hypnosis and, in humans, are accompanied by
a feeling of drunkenness and reduced cognitive function (e.g., dif-
ficulty in performing mental arithmetic), and (3) the effects of
antiabsence drugs against hypnotic drugs (and their EEG manifes-
tations) have not been tested, it would be prudent to withhold
judgment on whether, in primates, this stage actually models
human ASs (Table 3).
In the cat, 3 Hz SW complexes, along with trains of spikes and
isolated waves, are produced in stage 2. These activities bear mor-
phological similarity to human SWDs [55], but unfortunately the
sensitivity of this GHB-elicited activity to antiabsence and anticon-
vulsant drugs has not been tested.
In the rat, the intermittent spike and wave bursts of stage 2a
have similar EEG morphology to human SWDs. Importantly, the
motor behavior of the rats is also indicative of an AS, that is, freez-
ing for the duration of the EEG paroxysm and the resumption of
previous motor behavior upon its termination. Assessing an
impairment of consciousness in rats is even more challenging than
it is in humans [3]. Some strategies, such as comparing evoked
potential during sleep/SWDs [76] or looking at ictal stimulus
processing [77], have been performed in rat genetic models of
ASs, but not in the GHB model. Moreover, the frequency of GHB-
elicited SWDs is higher than that in humans. However, this fea-
ture is shared by all rat pharmacological and genetic models of
ASs. The reason for this phenomenon is unclear but it has been
suggested that it represents intrinsic interspecies differences [78].
Stage 2b (i.e., continuous hypersynchrony) in rats was origi-
nally suggested not to model ASs. This conclusion was based on
the fact that, behaviorally, the animals appear sedated (i.e., for
several minutes rats are not moving), and therefore there is no
evidence of interruption of a directed movement. Moreover, their
posture (i.e., the animals are sitting quietly with their belly on the
cage floor with a decreased muscle tone) is more suggestive of a
hypnotic state than of ASs. Finally, the morphology of the EEG
activity during stage 2b is different from that of the intermittent
bursts of spike and waves: their frequency is lower and less regu-
lar, and the spike component is often missing. It is striking
although that both stage 2a and 2b in rats have the same pharma-
cological profile, that is, they both respond to antiabsence drugs
(Table 2). As mentioned previously, the effect of antiabsence
drugs on the EEG and behaviors elicited by hypnotic drugs has
never been tested, but there is some evidence that ethosuximide
can reduce the duration of pentobarbital-induced sleep in rats
[79]. On the basis of all these issues, therefore, we suggest that the
more cautious interpretation at present is that, in rats, only stage
2a models ASs while stage 2b is more similar to sedation/hypnosis
(Table 3).
In mice, stages 2a and 2b are less well defined than in rats, and
no study has clearly described the transition between intermittent
bursts of spike and waves and continuous hypersynchrony and
their respective behavioral correlates. Isolated spike and waves in
mice, with sudden onset and termination, are sometimes difficult
to discern (see figure 3A and 5D in ref [69,80], respectively).
Moreover, the pharmacological characterization of GHB-induced
ASs in mice is still only partial, and some differences to the rat
GHB model, such as the unresponsiveness of stage 2 GHB-elicited
activities to valproate, have not been further investigated.
In conclusion, while the GHB model in the rat has been charac-
terized extensively, in other species, many important aspects of
this characterization are still missing. The fact that in all species
the activities of stage 2 are defined as ASs is misleading, and this
classification should be restricted to stage 2a in rats until further
investigation is carried out in other species (Table 3).
Anatomical Substrate of GHB-Induced
ASs
In this section, we describe the mapping of GHB-elicited activities
within the brain. In particular, given that most work has been car-
ried out in the rat, we will compare the features of the rat GHB
model with other well-characterized rat models of absence epi-
lepsy (namely GAERS and WAG/Rij) and with human data.
Thalamocortical Network
ASs are generated within the TC network [1,15]. Indeed, GHB-
induced ASs can be recorded simultaneously in cortex and thala-
mus in all the species in which this has been attempted, that is,
monkey [34], cat [33], and rat [81]. An extensive characterization
of the neuronal substrates of GHB-elicited seizures has been per-
formed in the rat with both ictal and interictal local field potential
(LFP) recordings in various brain areas [81] and with thalamic
electrical lesions [82]. Some marked differences emerged with
respect to other established rat models of ASs. Firstly, GHB-
induced SWDs were recorded only in superficial layers (I–IV) of
the fronto-parietal cortex and not in deep layers (V–VI). This is
surprising considering that in GAERS SWDs can be observed in
LFP recordings across all cortical layers. Furthermore, the initia-
tion site of ASs has been identified in layers V–VI of the somato-
sensory cortex in GAERS and WAG/Rij [83,84]. Secondly, SWDs
were recorded in all thalamic nuclei, including intralaminar
nuclei, with the exception of the ventrolateral nucleus [81]. Con-
versely, in GAERS, SWDs were present in the ventrolateral
nucleus, while the intralaminar nuclei were silent [61]. Moreover,
while lesions of the ventrobasal complex and NRT abolished ASs
in GAERS [85], in the GHB model, these lesions only reduced ASs
by 25% [82]. In addition, lesions of the intralaminar nuclei, which
are ineffective in GAERS [85], abolished GHB-induced ASs [82].
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Hippocampus
Human fMRI studies indicate that hippocampal structures are
generally silent during ASs [17–19], although to the best of our
knowledge, there has been no direct electrophysiological record-
ings in humans to confirm this. In genetic rat models of ASs, no
SWDs can be recorded in hippocampal territories [16,60], but they
are present in the hippocampus of stargazer mice [86].
In the case of the GHB model, most experimental studies
have shown that an ictogenic concentration of GHB induces
similar EEG activity in cortex and hippocampus. Parenteral
administration of an ictogenic concentration of GHB in cats
induced similar EEG activity, characterized by slow waves or
SW complexes that could be recorded in cortical, thalamic, and
hippocampal territories [33]. The same was true for the tha-
lamic administration of GHB in monkeys [34]. In rats, the
overwhelming fMRI [87] and electrophysiology [64,88] evi-
dence supports the presence of SWDs in the hippocampus dur-
ing GHB-elicited ASs (but see ref [81]).
Brain Targets of GHB: Molecular,
Biochemical, and Pharmacological
Evidence
The mechanism by which the EEG and behavioral effects of GHB
are produced is only partly understood. GHB is known to bind to
at least two populations of receptors in the brain: GABAB recep-
tors (GABABRs) and a putative GHB receptor (GHBR) [89,90].
Although most evidence converges to suggest that the hypnotic
and ictogenic activity of GHB is mediated by its activation of
GABABRs, a contribution of the putative GHB receptor is still
under debate [37,89,90]. In addition, it has been suggested that
some of the effects of GHB could be due to its conversion to GABA
[91] (see below). We will start by critically reviewing the evidence
for the existence of a GHBR. We then discuss the in vitro and in
vivo evidence that could link the activation of the putative GHBR
to GHB-induced ASs and hypnosis. We will concentrate on studies
that use GABABRs/GHBR antagonists and GHB at doses that are
relevant for the generation of ASs. Moreover, we will focus on
brain areas that are known to be important for the expression of
ASs in the GHB model, that is, the TC network, but also on the
hippocampus where GHB-elicited SWDs have been recorded in
rats (as discussed above). For a summary of GHB-elicited actions
in other brain areas, readers are referred to relevant reviews
[89,92].
Molecular Identity of the Putative GHBR
The existence of a GHBR was originally suggested by the pres-
ence of high affinity (nM) binding sites for GHB in the rat
brain [93]. This specific binding starts to be observed at post-
natal day 15–18 and reaches full expression at 3–4 weeks
postnatally; binding is most intense in the hippocampus, cor-
tex, thalamus, and amygdala, with the cerebellum showing
very low binding levels [94]. These high affinity sites do not
correspond to GABABRs, to which GHB binds only with low
affinity (in the lM range) [31,95]. This is demonstrated by
the fact that GHB binding on the high affinity binding sites
cannot be displaced by GABA or baclofen [31] and that the
high affinity binding sites are spared in GABAB knockout mice
[96,97]. The molecular identity of the GHBR(s) is at present
unknown and has been the subject of controversy for the last
30 years. The high affinity GHB binding sites are increased
during GHB-induced ASs [81] and in the thalamus of adult
GAERS rats compared to nonepileptic controls [98], although
it is not clear whether this is a cause or a consequence of
ASs.
Initially, the presence of the GHBR was studied using various
compounds able to displace GHB binding on the high affinity GHB
binding sites. These compounds would be, in principle, useful
tools to understand the cellular effects of activation/inhibition of
the putative GHBR, but unfortunately their intrinsic properties
are unclear. The best-characterized GHBR ligand is NCS-382
which, as well as displacing GHB in binding studies, was shown to
antagonize GABAB-independent GHB effects at least in a limited
number of studies (described in the following sections). Several
GHB analogs have also been produced (reviewed in [99,100]), but
there is very little evidence, in vivo or in vitro, that these com-
pounds activate the putative GHBR (i.e., that they mimick GABAB
-independent effects of GHB).
From this analysis, it is clear that the controversy on the role of
the GHBR is unlikely to be resolved until the molecular identity of
the protein comprising the high affinity binding site of GHB is
fully isolated. In that respect, there have been two reports of the
identification of a high affinity molecular target of GHB. In 2003,
Andriamampandry et al. [101] described the cloning of a rat GHB
receptor. Nonetheless, this putative GHB receptor does not bind
NCS-382 and its expression only partially overlaps with the GHB
high affinity binding site [101]. For instance, it is highly expressed
in the cerebellum, an area with the lowest expression of GHB high
affinity binding sites [94].
In 2012, a study by Absalom et al. [102] reported that extrasy-
naptic GABAA receptors (GABAARs), and in particular the a4b1d
GABAAR, could represent a population of the elusive GHB recep-
tors. Indeed, a4b1d receptors expressed in xenopus oocytes were
activated by nM concentrations of GHB. Using autoradiography,
GHB, and gabazine, but not GABA, were shown to displace the
novel GHBR ligand [125I]BnOPh-GHB. Furthermore, it was
reported that NCS-382 binding was reduced by ~40% in a4 knock-
out mice [102]. This discovery could be of great importance
because extrasynaptic GABAARs are responsible for the tonic
GABAA current, which has been shown to be increased in the
thalamus in various models of ASs [103], and to influence sleep
and anesthesia [104]. Nonetheless, the relevance of these observa-
tions to native brain tissue has recently been called into question.
In fact, it has been demonstrated that, in thalamus, hippocampus,
and cerebellum, three regions where a4b1d GABAA receptors are
highly expressed, lM concentrations of GHB were not able to
evoke any activity on extrasynaptic GABAARs [105]. In addition,
mM concentrations of GHB could only evoke activity dependent
on GABABRs. All these observations, together with the fact that
the binding of NCS-382 to a4b1d receptors was not tested, means
that the identity of the high affinity binding site of GHB is still
uncertain.
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Putative GHBR-Mediated Effects: ASs,
Cellular Excitability, and Synaptic
Potentials
Controversy also still surrounds the effect of systemic administra-
tion of the GHB antagonist NCS-382 on ASs. It was initially
reported that the compound blocked various GHB-induced effects
such as cataplexy, hypolocomotion, and ASs [106,107], but more
recent studies have reported a lack of effects [108–110] or even an
aggravation of GHB-induced activities [100,111]. In addition, high
doses of NCS-382 were able to drastically reduce SWDs induced
by PTZ [112] and spontaneous ASs in GAERS [107] and lethargic
mice [113], suggesting that its effects are not specific to the GHB
model. Finally, putative agonists for the GHBR (e.g., trans-hy-
droxycrotonic acid (THCA), which displaces GHB from its high
affinity binding sites, but does not bind to GABABRs [93]), did not
induce ASs in na€ıve animals or exacerbate seizures in GAERS
[100,114].
As far as potential GHBR-mediated effects of GHB are con-
cerned, an in vivo study in anesthetized mice showed that NCS-
382 blocked the increase in long-term potentiation in the hippo-
campus elicited by systemic GBL (50 mg/kg) [113]. Unfortu-
nately, the effect of GABABR antagonists, that blocked a similar
increase in long-term potentiation induced by baclofen, was not
tested against the GBL action [113]. Another in vivo study in anes-
thetized rats reported that systemic GHB (5–10 mg/kg) first
decreased and then increased the firing rate of unidentified corti-
cal layer III–VI neurons, with the latter effect being blocked by
NCS-382 [115]. The results of these studies should be interpreted
with caution as effects resulting from systemic administration of
GHB (and NCS-382) may involve actions that are not direct on
the recorded neurons or the brain region under investigation.
A direct action on hippocampal neurons was shown in in vitro
studies on CA1 pyramidal neurons, where GHB reduced the
amplitude of both EPSPs (at 600 lM) and IPSPs (at 100–1200 lM)
[116,117]. Importantly, the effects of GHB were antagonized by
NCS-382 but were not affected by GABABR antagonists. Another
NCS-382-dependent action in the hippocampus is the increase in
glutamate levels observed after local microdialysis application of
100–500 nM of GHB [118,119]. Interestingly, an increase in glu-
tamate levels was also obtained with the putative GHBR agonist
THCA [118]. In contrast, microdialysis of 1 mM GHB elicited a
decrease in hippocampal glutamate levels that was only partially
blocked by NCS-382 but fully antagonized by GABABR antago-
nists [119].
GABABRs as Targets of GHB
GHB is a weak agonist at GABABRs: it displaces binding of the
GABAB agonist baclofen with a Kd in the range of 30–500 lM
[31,95] and activates heterologous GABABRs with an EC50 in the
low mM range [120]. This is particularly significant considering
the concentration of endogenous GHB in the brain is 1–4 lM
[121,122] and that the threshold brain concentration of GHB that
correlates with the onset of an AS phenotype is 240 lM [39]. Fur-
thermore, the hypnotic/anesthetic concentration of GHB in the
brain (measured when animals regain their righting reflex after
bolus i.v. administration of GHB) is 400 lM [123]. Therefore, icto-
genic and anesthetic/hypnotic concentrations of GHB are compat-
ible with activation of GABABRs.
Global Blockade of GABABRs: Effects on ASs and
Behavior
Most, if not all, behavioral effects, including ASs [112,124] and
hypnosis/anesthesia [125], induced by exogenous GHB adminis-
tration in vivo, can be blocked by GABABR antagonists (reviewed
in [125]), whereas the sensitivity of the putative sleep-inducing
effect of low doses of GHB (e.g., 50 mg/kg in the rat, [57,58]) to
these drugs has not been tested. Recently, experiments in
GABABR knockout mice have provided compelling evidence that
the majority of the effects induced by GHB are dependent on the
presence of these receptors. At a range of doses that encompass
the sedative, pro-epileptic and anesthetic concentrations of exoge-
nously administered GHB (50–300 mg/kg), no effects were
observed in these knockout mice [68,96].
Finally, the potent and selective GABAB agonist baclofen
induces similar EEG and behavioral effects to GHB, both in terms
of an AS-like phenotype [112] and anesthetic action [126]. None-
theless, the effects of systemic baclofen have not been fully char-
acterized as an absence epilepsy model (e.g., pharmacological
profile, anatomical substrates of SWDs, etc.) so the association of
baclofen to an AS phenotype remains tentative.
GHB Activation of GABABRs in the Thalamus
In vitro studies in slice preparations of the cat and rat thalamus
have demonstrated multiple postsynaptic effects of GHB on TC
neurons. GHB elicits a membrane hyperpolarization on TC
cells; this effect is dose-dependent starting from 100 lM (the
lowest concentration tested) to 3 mM (the plateau of the effect)
[127]. The effect was mediated by the opening of potassium
channels and, at the doses tested (400 lM–1 mM), was blocked
by a GABABR antagonist. Recent work has also produced evi-
dence of another important thalamic postsynaptic effect of
GHB: an increase in tonic GABAA inhibition [103] (see below).
This effect is postsynaptic and is mediated by GABABRs via a
G-protein-dependent pathway that probably results in dephos-
phorylation of extrasynaptic GABAARs [128].
Presynaptic effects induced by GHB on TC cells have also been
described: GHB reduced the amplitude of sensory and corticotha-
lamic EPSPs [129,130]. The minimum concentrations of GHB to
induce these reductions were 100 lM and 250 lM, respectively.
Interestingly, GABA IPSPs originating from the NRT were only
reduced by GHB concentrations ≥500 lM [130]. All these effects
were blocked by GABAB antagonists, while NCS-382 was either
ineffective or had a tendency to potentiate the effects of GHB
[129,130].
Finally, an in vivo study looked at the effects of GHB, injected
systemically or in the ventrobasal thalamus by reverse microdialy-
sis, on basal and K+-evoked glutamate and GABA levels [65].
Starting from a concentration of 250 lM, GHB reduced basal
GABA levels, leaving basal glutamate levels unchanged; both
GABA and glutamate K+-evoked levels were instead reduced. A
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similar effect on levels of these neurotransmitters in the ventroba-
sal thalamus was observed during GHB-induced ASs. These effects
were fully blocked by systemic application of GABAB antagonists
but only partially antagonized by NCS-382 [65]. Nonetheless, the
significance of changes of basal and K+-evoked levels of neuro-
transmitters for local network activities are difficult to predict in
the absence of electrophysiological data on neuronal firing
dynamics.
GHB Activation of GABABRs in the Cortex
An in vivo study [131] in anesthetized rats showed that systemic
administration of GHB at 100 mg/kg had no effect or a tendency
to increase the firing rate of unidentified pyramidal cells, whereas
300 mg/kg produced decreases in the firing rate. In another inves-
tigation [115], systemic injection of GHB (160–320 mg/kg)
decreased the firing rate followed by a rebound increase. These
effects were not sensitive to NCS-382, but GABAB antagonists
were not tested. The paucity of in vivo electrophysiological studies
does not allow us to draw a clear conclusion on the effects on
GHB on the cortex in vivo. In addition, as mentioned earlier, the
possibility remains that the effects observed after systemic admin-
istration of GHB are indirect.
An in vivo dialysis study investigated basal and K+-evoked
release of GABA and glutamate in the superficial layers of the cor-
tex [132]. While glutamate concentration was unchanged, there
was a clear reduction of both basal and K+-evoked GABA levels.
This effect was blocked both with GABAB antagonists and with
NCS-382. It is worth noting that the effects on GABA release
ended within 70 min, while ASs persisted for 2 h. It is therefore
unclear if these effects simply co-occur with ASs after GBL appli-
cation or if they have a mechanistic role in their expression.
Experiments in slice preparations from the mouse frontal
cortex have shown that, similar to the thalamus, GHB induces
a hyperpolarization both of pyramidal cells and putative inter-
neurons in layer II/III, with the difference that the threshold
to obtain this effect was reported to be in the mM range
[133]. In addition, GHB (1 mM) caused a depression in both
amplitude and frequency of miniature EPSPs and IPSPs via a
presynaptic mechanism. A more recent study [134] in the rat
prefrontal cortex demonstrated that 300 lM of GHB was suffi-
cient to reduce the amplitude of NMDA-EPSPs in layer II/III
pyramidal cells. AMPA EPSPs and IPSPs were only depressed at
a concentration of 1 mM. All the aforementioned effects, either
in mouse or rat, were fully antagonized by GABAB antagonists,
while NCS-382 was ineffective against the GHB-elicited depres-
sion of postsynaptic potentials [133,134].
GHB Activation of GABABRs in the Hippocampus
As discussed above, the hippocampus, the area with the highest
expression of GHB high affinity binding sites, is also the only area
where it is possible to observe clear electrophysiological effects of
GHB that are antagonized by NCS-382, but not by GABAB antago-
nists. Nonetheless, in the hippocampus, GHB can also elicit
GABAB specific effects. An early study reported that, similar to
cortex and thalamus, GHB produces a GABAB-dependent hyper-
polarization of CA1 pyramidal neurons [135]. In contrast to the
work of Berton et al. [116](described above), 1 mM GHB
decreased EPSPs and IPSPs via GABABR-mediated action [136].
GHB Effects on Astrocytes: Actions on
GHBR and GABABRs
Although astrocytes were once considered to have only a struc-
tural function in the brain, they have now been shown to play
a substantial role in synaptic physiology [137,138]. Moreover,
a role for astrocytes in genetic models of ASs is being increas-
ingly recognized [139]. Less is known about the effects of GHB
on astrocytes of the TC network. A recent study [140], how-
ever, has shown that GHB dose-dependently induced a tran-
sient increase of intracellular Ca2+ in astrocytes of the rat
ventrobasal thalamus, with an ED50 of 1.6 mM and a minimal
effective concentration of 250 lM. These GHB-elicited astro-
cytic Ca2+ transients were abolished by GABABR antagonists
and absent in GABABR knockout mice. Similar results were
obtained with the GABAB agonist baclofen. NCS-382 was inef-
fective in blocking the baclofen-evoked Ca2+ transients but
drastically reduced those elicited by GHB. These results suggest
that activation of GABABRs is necessary to produce Ca
2+ tran-
sients in thalamic astrocytes [140].
Metabolic Conversion of GHB to GABA
The possibility that the effects of exogenously administered
GHB may be due to its metabolic conversion to GABA (which
occurs via a cytosolic GHB dehydrogenase [31,141]) has been
debated for many years [91,95]. Several lines of evidence,
however, strongly suggest that the amount of GHB metabolized
to GABA is not substantial, especially at GHB concentrations
relevant for its pro-epileptic/hypnotic actions. Firstly, the elec-
trophysiological effects of GHB are blocked by GABAB antago-
nists but not by GABAA antagonists. Yet, if GHB were
converted to GABA, an effect on both receptors would be
expected. Secondly, in GABAB knockout mice, high doses of
GHB (>1000 mg/kg) do not induce phenotypes that would be
expected from an increased GABAAR activation (as discussed
above). Thirdly, ethosuximide and valproate at concentrations
that inhibit the GHB dehydrogenase [141] had no effect on
GHB effects mediated by GABABRs [95,134,142]. In conclu-
sion, the current evidence strongly supports the view that the
ability of exogenously administered GHB to induce ASs does
not depend on its metabolic conversion to GABA.
Mechanism of GHB-Induced ASs in the
Rat
In this section, we describe potential mechanisms for the genera-
tion of GHB-elicited ASs in rats. As discussed above, we define
GHB-induced ASs only the EEG and behavioral activity that is
characteristic of stage 2a in this species. Moreover, it is worth not-
ing that, compared to the thorough mechanistic description of
spontaneous ASs in genetic models of absence epilepsy, there is a
paucity of studies exploring the mechanisms of the GHB-elicited
ASs. In particular, in GAERS and WAG/Rij [83,84], as well as in
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humans [18,19], there is evidence of a cortical initiation site.
Whether this is the case in the GHB model remains to be
ascertained, although there is some evidence that, within the cor-
tex, seizures are initiated in the primary somatosensory cortex
[143]. In addition, in GAERS, intracellular or extracellular record-
ings from thalamic and cortical neurons have provided a clear
view of their firing dynamics during ASs, in vivo [83,144,145],
whereas a similar description is not available for GHB-elicited ASs.
In view of the in vitro and in vivo evidence presented in the
previous sections, it seems safe to assume that GHB, acting as a
weak agonist on GABABRs, is responsible for the electrophysiolog-
ical effects observed in the TC network. At brain concentrations
relevant for the expression of ASs (i.e., 240 lM), GHB induces a
postsynaptic hyperpolarization on corticothalamic and TC
neurons and, both in the ventrobasal thalamus and in the frontal
cortex, presynaptically depresses EPSPs, therefore favoring phasic
inhibition over phasic excitation.
In addition, several lines of evidence suggest that GHB activa-
tion of GABABRs in the thalamus is involved in the generation of
SWDs. Intrathalamic and systemic administration of GHB pro-
duces similar EEG and behavioral activities in both monkeys [34]
and rats [39], as does intrathalamic administration of baclofen
[146]. Another indication of the role of the thalamus in the
expression of GHB-elicited ASs has come from work on thalamic
tonic GABAA inhibition. This type of inhibition is increased in sev-
eral animal models of absence epilepsy compared to nonepileptic
controls and this has been shown to be causally linked to the
expression of the disease [103,147]. GHB (300 lM) produces a
~30% increase in tonic GABAA current [103], an effect that is
mediated by a postsynaptic cross-talk between GABABRs and
GABAARs [128] (as discussed above).
Therefore, GHB acts on TC neurons with at least three
independent mechanisms that could facilitate/generate ASs:
presynaptically by an indirect increase in phasic GABAA
inhibition, and postsynaptically by membrane hyperpolarization
and an increase in GABAA tonic inhibition. Notwithstanding
this evidence, a contribution of the cortex in the generation of
GHB-induced ASs cannot be ruled out. If the identification of
a cortical initiation site in GHB-elicited ASs were to be con-
firmed, it could open new avenues of investigation on the cor-
tical contribution to the generation of GHB-induced ASs.
Finally, the lack of in vivo recordings of cortical and thalamic
neurons during GHB-elicited ASs does not allow us, at present,
to predict how the aforementioned in vitro mechanisms con-
verge to evoke an AS.
Voltage- and Neurotransmitter-Gated
Channels in the GHB Model
The GHB model has been used to understand the contribution of
various voltage- and neurotransmitter-gated channels to the
expression of ASs. Broadly speaking, these experiments can be
divided into two main sets: (1) pharmacological manipulations,
with intracerebral or systemic drug application in rats, and (2)
experiments using the GHB model in knockout mice. We will dis-
cuss these experiments in separate sections to account for the
aforementioned problems with the GHB model in mice.
Pharmacological Manipulations in the Rat
Systemic administration of both NMDA agonists and antagonists
blocked the expression of GHB-elicited SWDs but also induced a
burst-suppression pattern [148]. Bilateral infusion of NMDA in
thalamic nuclei and in the NRT suppressed the expression of
GHB-elicited SWDs [149]. As far as the GABAergic system is con-
cerned, systemic administration of the GABAA agonist muscimol
[150], or of weak GABAA antagonists (PTZ, penicillin), induced an
increase in GHB-elicited ASs [36]. Systemic and intrathalamic
administration of steroid modulators of GABAA receptors (alphax-
alone, ganaxolone, tetrahydrodeoxycorticosterone) exacerbated
GHB-elicited SWDs [151,152]. Importantly, caution should be
exerted in interpreting the results of all these studies, as in all of
them, both stage 2a and stage 2b of GHB-elicited activities (i.e.,
ASs and hypnosis) were analyzed together.
Genetic Manipulations in the Mouse
In the last decade, different mouse knockouts have been used to
investigate the role of specific genes in the expression of GHB-elic-
ited ASs and may, ultimately, provide some indication of the
genetic abnormalities underlying these nonconvulsive seizures in
humans. For example, metabotropic glutamate receptor 4 knock-
out mice were resistant to ASs induced by GABAA antagonists
(PTZ, bicuculline), while GBL (100 mg/kg) and baclofen elicited
ASs as in wild-type littermates [71]. Moreover, knockout mice for
the AMPA subunit GluR2 had a lower latency of onset, and a
decreased cumulative duration of GHB-elicited ASs (GBL 100 mg/
kg) compared to their wild-type littermates [153].
T-type Ca2+ channels have long been thought to play a role in
ASs [154]. Mice lacking the a1G T-Type Ca2+ channel gene, and
which therefore do not express functional Cav3.1 channels, were
resistant to GHB-elicited seizures (GBL i.p. 70 mg/kg), while the
susceptibility of these knockout mice to GABAA antagonist-elic-
ited ASs was unchanged [69]. CaV2.3 channel (R-type) knockout
mice displayed a reduced cumulative time spent in seizure and
reduced seizure length after systemic application of GBL (70 mg/
kg) [155].
Mice lacking the GABAAR a3 subunit had a reduced length and
amplitude of GHB-elicited ASs (GBL 100 mg/kg) compared to
their wild-type littermates, and a similar result was found for
systemic PTZ-induced ASs [80]. In contrast, mice lacking the d
subunit of the GABAAR were resistant to GHB-induced ASs
(50 mg/kg GBL) [103].
Of course, caution is needed in drawing mechanistic conclu-
sions from these experiments as the global deletion of a gene
in the CNS causes the loss of a protein that is often expressed
in multiple brain areas which are part of, or project to, the TC
network that is ultimately responsible for AS generation. In
addition, GHB does not bind, nor has any direct electrophysio-
logical effects on, either iono/metabotropic glutamate receptors,
voltage-gated Ca2+ channels or GABAARs (except at extrasy-
naptic GABAARs, as discussed above). Therefore, the results of
all the studies presented above inform us about proteins that
are necessary for the expression of GHB-elicited ASs at the
network level, but not about direct targets of the molecule.
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Moreover, given that these experiments have been performed
in mice, where the GHB model is only partially characterized,
it is difficult to predict whether these findings on knockout
mice apply to the mechanism by which GHB induces ASs,
hypnosis or both. Thus, crossing the aforementioned knockout
mice with genetic mouse models of absence epilepsy (e.g., star-
gazer, tottering or lethargic mice) could be a useful tool to test
independently the contribution of individual genes to the
expression of ASs. Finally, it is noteworthy that the knockout
of some of these genes has no effect on GABAA antagonist-
induced SWDs while abolishing GHB-induced ASs [69] or vice
versa [71]. Although the reasons of this difference are at pres-
ent unclear, this finding clearly points to multiple independent
mechanisms underlying the generation of ASs induced by dif-
ferent pharmacological agents, as previously suggested
[154,156], and, importantly, provides support to the hypothesis
that different and independent genetic abnormalities may
underlie human ASs in various patient cohorts [1].
Summary
To help the reader, here we summarize the main points arising
from our analysis of the GHB model and highlight the most press-
ing questions that remain unanswered.
Only GHB-Elicited Stage 2a Models ASs in the
Rat
Both in rats and in mice, where the GHB model has been
extensively used, researchers tend to identify all activities
evoked by a nonanesthetic dose of GHB as ASs. We argue that
this classification is incorrect as it lumps together activities that
resemble ASs with others that represent a sedated/hypnotic
state. Stage 2a in rats (Table 3), where the animals display
SWDs accompanied by behavioral arrest, has been thoroughly
characterized, in terms of EEG and behavior, and has the same
face validity as genetic AS models. Stage 2b, where the EEG
paroxysm becomes continuous and is accompanied by changes
in body posture and muscle tone that more closely resemble
hypnosis than ASs, should be considered as a distinct phenom-
enon. This classification has important consequences for the
practical use of the GHB model. For instance, in rats, stage 2a
has much shorter cumulative duration than stage 2b. Upon
injection of 200 mg/kg GHB, stage 2a has 5–8 second long
SWDs that occur intermittently over 10 min, whereas stage 2b
has continuous hypersynchronous EEG and hypnosis lasting
~20 min, [58]. Therefore, the results of many studies are
skewed toward the hypnotic effects of GHB rather than GHB-
elicited ASs. Finally, the practice of considering stage 2a and
stage 2b together seems to be driven mainly by pharmacologi-
cal considerations. Undoubtedly, the unique pharmacological
profile of ASs should contribute toward defining a model of
ASs (as it defines the model predictive validity) (Table 2), but
cannot be used as a substitute for EEG and behavior that
resembles, that is, has face validity for, ASs. In this respect, a
direct comparison, in the same animals, of the effect of eth-
osuximide, valproate, carbamazepine, and phenytoin on the
EEG and behavior of GHB stage 2a and 2b versus sedation,
hypnosis, and natural slow-wave sleep could be of great
significance.
The GHB Model in the Mouse
The GHB model in the mouse is not as well characterized as
in the rat. In particular, (1) the EEG of stage 2a appears to
vary greatly between studies (Figure 1F2), and an EEG mor-
phology with clear spikes is rarely observed; (2) as mentioned
previously for the rat, in a model of ASs, SWDs should be
accompanied by behavioral arrest: a prolonged lack of move-
ments accompanied by a decrease of muscle tone and change
in body posture [67,68,157], as observed in stage 2b in mice,
is more reminiscent of an hypnotic state than ASs; (3) the
pharmacological characterization of the GHB model in mice is
incomplete. It is only by resolving these issues that we will be
able to accept, with confidence, the GHB model in mice. Nev-
ertheless, administration of GHB to mice has opened interest-
ing questions about the different mechanisms that underlie
ASs induced by either GABAB agonists (i.e., GHB, baclofen)
and GABAA antagonists (i.e., PTZ, bicuculline), which are
worth investigating further.
EEG Seizure Properties in the GHB Model
While it has been suggested that ASs in the GHB model can be
quantified in the same way as in polygenic rat models [25,158], it
appears from the literature that the information available for vari-
ous seizure parameters, for example, average seizure length, mor-
phology of SWDs, dominant frequency, etc) (Table 1) is scarce or
contradictory. This may be, in part, due to a lack of consensus
regarding which of the activities evoked by exogenous, GHB
administration represents an AS [36,58,64]. Moreover, current
seizure detection methods for the GHB model have not been
shown to be able to discriminate between sleep, hypnosis and ASs
[69,80].
Molecular Targets of GHB
It is now well accepted that most, if not all, effects of exogenously
administered GHB depend on its agonist action on GABABRs.
Activation of the putative GHBR does not underlie the pro-
epileptic and hypnotic effects of GHB.
Role of the Hippocampus in the GHB Model
It is remarkable that GHB-induced ASs can be recorded in the hip-
pocampus as limbic structures are not normally associated with
typical ASs [1,20]. Importantly, the hippocampus is the brain
region with the highest expression of GHB high affinity binding
sites and where some electrophysiological evidence exists of
GABABR-independent GHB effects. Nonetheless, mice overex-
pressing the GABABR1a subtype have an atypical AS phenotype
which involves, along with other neurological symptoms, the
presence of SWDs that are not necessarily associated with behav-
ioral arrest and that can be recorded in hippocampal territories
[159]. Further studies are needed to understand the role of the
hippocampus during GHB-induced ASs and the role that activat-
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ing hippocampal GABABRs/GHBR plays in the genesis of typical
and atypical ASs.
Role of Thalamus and Cortex in the Expression
of GHB-Elicited ASs
Many converging studies suggest that the thalamus is a key area
in the generation of GHB-elicited ASs. Various pre- and
postsynaptic mechanisms have been described in TC neurons. In
particular, GHB increases the tonic GABAA current, a key factor in
the generation of ASs [103]. This effect, produced by a cross-talk
between GABAB and extrasynaptic GABAA receptors [128], has
emerged as a new player in the thalamic contribution to the
generation of ASs. As far as the cortex is concerned, in contrast to
current notions, on how ASs are generated and propagated [1,83],
deep layers of the cortex are silent during GHB-induced ASs in the
rat [81]. This issue needs to be further investigated in vivo, using
simultaneous recordings of LFP and unit activity across cortical
layers.
Conclusions
Although the link between GHB and ASs dates back to more than
50 years [32,33], the description of the cellular, molecular, and
behavioral aspects of the GHB model has fallen behind compared
to our understanding of the genetic models of ASs. Nonetheless,
pharmacological models of ASs such as the GHB model are still
important: the mechanistic knowledge of how targeting a single
receptor can acutely bring about an ASs represent great advantage
with respect to polygenic rat models of ASs, where the underlying
genetic abnormalities are unknown, and monogenic mouse mod-
els of ASs, which have other comorbidities and where develop-
mental changes to network excitability cannot be easily tracked.
Human ASs are a complex phenomenon which accompanies a
wide range of epilepsies (in pediatric, juvenile, and adult patient
cohorts). To further understand the pathophysiology of ASs, there
is a clear need to have different tools, and thus answering the
issues highlighted in this review is necessary to make the GHB
model one of such indispensable tools.
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